加载中
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
前收盘价
US$9.77
−US$0.21 · -2.10%
盘前
US$9.73
−US$0.04 · -0.41%
10月8日 8:01 ET
盘中时间采用ET。市场数据可能有所延迟。
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
日内区间
当前US$9.77
52周区间
当前US$9.77
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
15
估值过高
情绪
44
多空交织
风险
56
风险偏高
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
日内区间
当前US$9.77
52周区间
当前US$9.77
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 1572.8万 USD | 484.4万 USD | 570.8万 USD |
| 销货成本 | — | 681.39万 USD | — | — | 1039.1万 USD |
| 毛利 | — | −681.39万 USD | 1572.8万 USD | 484.4万 USD | −468.3万 USD |
| 研究与开发 | 1.17亿 USD | 8990.19万 USD | 6022.3万 USD | 7554.3万 USD | 7033.6万 USD |
| 销售、一般及管理费用 | 3601万 USD | 2381.09万 USD | 3193.8万 USD | 2593.2万 USD | 2382.7万 USD |
| 营业费用 | 1.47亿 USD | 1.14亿 USD | 9216万 USD | 1.01亿 USD | 9393.1万 USD |
| 利息收入 | 60.1万 USD | 272.6万 USD | 371.4万 USD | 42.7万 USD | 52.1万 USD |
| 利息支出 | — | — | — | — | 69万 USD |
| 折旧和摊销 | 319.4万 USD | 681.39万 USD | 1316.2万 USD | 1316.2万 USD | 837.6万 USD |
| 营业利润 | −1.47亿 USD | −1.21亿 USD | −7643.2万 USD | −9663.1万 USD | −9861.4万 USD |
| 净利润 | −1.47亿 USD | −1.14亿 USD | −7272.6万 USD | −9627.4万 USD | −9780.9万 USD |
公司数据更新于 2026年10月8日。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
